September 22, 2026
Thiogenesis Therapeutics Corp.
ISIN: CA88410L1022
Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update
San Diego, California, September 21, 2026 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today...
Read more >>Thiogenesis Appoints Dr. Gilad Aharon to its Board of Directors
SAN DIEGO, CA - June 17, 2026 - Thiogenesis Therapeutics, Corp. (TSXV: TTI; OTCQX: TTIPF) (“Thiogenesis” or the “Company”), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr....
Read more >Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue Improvement San Diego, California – January 23, 2026 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation thiol-based prodrugs for rare mitochondrial and pediatric diseases, today announced the presentation of...
Read more >